R.H. Bluestein & Co’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $2.45M | Sell |
30,414
-566
| -2% | -$47.9K | 0.15% | 58 |
|
|
2022
Q2 | $2.31M | Sell |
30,980
-672
| -2% | -$61.3K | 0.14% | 59 |
|
|
2022
Q1 | $4.05M | Sell |
31,652
-228,664
| -88% | -$25M | 0.17% | 54 |
|
|
2021
Q4 | $34.9M | Buy |
260,316
+1,744
| +0.7% | +$251K | 1.25% | 30 |
|
|
2021
Q3 | $35.4M | Buy |
258,572
+14,344
| +6% | +$1.81M | 1.4% | 31 |
|
|
2021
Q2 | $26.1M | Buy |
244,228
+15,112
| +7% | +$1.45M | 1.01% | 36 |
|
|
2021
Q1 | $20.6M | Buy |
229,116
+44,048
| +24% | +$4.13M | 0.87% | 42 |
|
|
2020
Q4 | $17.1M | Buy |
185,068
+22,096
| +14% | +$1.97M | 0.76% | 45 |
|
|
2020
Q3 | $16.8M | Sell |
162,972
-624
| -0.4% | -$65.2K | 0.84% | 38 |
|
|
2020
Q2 | $16.6M | Buy |
163,596
+32,264
| +25% | +$2.89M | 0.93% | 36 |
|
|
2020
Q1 | $8.84M | Buy |
131,332
+98,384
| +299% | +$6.12M | 0.75% | 30 |
|
|
2019
Q4 | $1.8M | Sell |
32,948
-2,340
| -7% | -$111K | 0.09% | 53 |
|
|
2019
Q3 | $1.32M | Sell |
35,288
-912
| -3% | -$35.4K | 0.07% | 55 |
|
|
2019
Q2 | $1.36M | Hold |
36,200
| – | – | 0.07% | 56 |
|
|
2019
Q1 | $1.08M | Sell |
36,200
-200
| -0.5% | -$7.03K | 0.06% | 66 |
|
|
2018
Q4 | $1.09M | Sell |
36,400
-1,432
| -4% | -$45.4K | 0.09% | 51 |
|
|
2018
Q3 | $1.35M | Sell |
37,832
-32
| -0.1% | -$992 | 0.07% | 64 |
|
|
2018
Q2 | $899K | Buy |
37,864
+3,564
| +10% | +$75.6K | 0.05% | 85 |
|
|
2018
Q1 | $636K | Sell |
34,300
-600
| -2% | -$8.87K | 0.03% | 128 |
|
|
2017
Q4 | $501K | Hold |
34,900
| – | – | 0.03% | 145 |
|
|
2017
Q3 | $427K | Sell |
34,900
-818,416
| -96% | -$14.5M | 0.02% | 182 |
|
|
2017
Q2 | $15.6M | Buy |
853,316
+113,628
| +15% | +$2.1M | 0.9% | 40 |
|
|
2017
Q1 | $15.7M | Buy |
739,688
+335,956
| +83% | +$6.56M | 0.94% | 39 |
|
|
2016
Q4 | $6.03M | Buy |
403,732
+383,732
| +1,919% | +$6.8M | 0.39% | 41 |
|
|
2016
Q3 | $438K | Buy |
20,000
+8,000
| +67% | +$178K | 0.03% | 126 |
|
|
2016
Q2 | $238K | Buy |
+12,000
| New | +$204K | 0.02% | 234 |
|
|
2016
Q1 | – | Sell |
-52,000
| Closed | -$1.06M | – | 294 |
|
|
2015
Q4 | $1.06M | Sell |
52,000
-6,000
| -10% | -$125K | 0.07% | 72 |
|
|
2015
Q3 | $1.25M | Buy |
58,000
+4,000
| +7% | +$89.2K | 0.09% | 66 |
|
|
2015
Q2 | $1.08M | Hold |
54,000
| – | – | 0.07% | 90 |
|
|
2015
Q1 | $842K | Hold |
54,000
| – | – | 0.05% | 102 |
|
|
2014
Q4 | $743K | Hold |
54,000
| – | – | 0.05% | 128 |
|
|
2014
Q3 | $540K | Hold |
54,000
| – | – | 0.03% | 183 |
|
|
2014
Q2 | $535K | Hold |
54,000
| – | – | 0.03% | 192 |
|
|
2014
Q1 | $558K | Buy |
54,000
+16,000
| +42% | +$165K | 0.04% | 176 |
|
|
2013
Q4 | $336K | Hold |
38,000
| – | – | 0.02% | 250 |
|
|
2013
Q3 | $268K | Hold |
38,000
| – | – | 0.02% | 278 |
|
|
2013
Q2 | $213K | Buy |
+38,000
| New | +$182K | 0.02% | 293 |
|
Other funds holding DXCM
R.H. Bluestein & Co's DXCM Position: Q3 2022 in Review
R.H. Bluestein & Co reduced its DexCom (DXCM) stake by 1.8% in Q3 2022, selling an estimated $47.9K and leaving 30,414 shares worth $2.45M. The position accounts for 0.15% of the portfolio, ranked #58.
R.H. Bluestein & Co first reported a position in DXCM in Q2 2013 and has held it in 37 quarters since. The position peaked at $35.4M in Q3 2021. 794 funds tracked by Wall St. Rank hold DXCM as of Q3 2022.
- R.H. Bluestein & Co held 30,414 shares of DexCom worth $2.45M as of Q3 2022.
- R.H. Bluestein & Co sold 566 DexCom shares in Q3 2022, an estimated $47.9K.
- DexCom made up 0.15% of R.H. Bluestein & Co's portfolio in Q3 2022, its #58 holding.
- R.H. Bluestein & Co first reported a position in DexCom in Q2 2013 and has held it in 37 quarters since.
- R.H. Bluestein & Co's DexCom position peaked at $35.4M in Q3 2021.
- 794 funds tracked by Wall St. Rank held DexCom as of Q3 2022.
Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.